EGFR and non-small cell lung carcinoma: EGFR inhibitors, including EGFR-tyrosine kinase inhibitors (TKIs) and anti-EGFR antibodies, can suppress cancer cell proliferation in NSCLC, CRC, and HNSCC, expressing aberrant EGFR ligands [5].